The presentations are routine scientific updates with no regulatory or financial catalysts. Monitor for future AXS-12 NDA filing timing and any solriamfetol label expansion updates as material next steps, but this filing provides no new trade-triggering information.
AXSM drugs
AXSM drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 15 $253.40entry
- T+1 · 5mo ago −0.59%α +0.01% · $251.91
- T+5 · 5mo ago −2.19%α −0.81% · $247.85
- T+20 · 4mo ago −9.91%α −9.16% · $228.28
- T+60 · 2mo ago −16.88%α −17.88% · $210.63
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Axsome Therapeutics presented new data on AXS-12 and solriamfetol at SLEEP 2026, including cognitive/functional outcomes from the Phase 3 ENCORE trial and post-hoc composite endpoint analyses. The presentations do not contain new regulatory milestones, financial results, or concrete catalysts, this is a routine scientific conference update without material new information for the stock.
Key Facts
- Presented Phase 3 ENCORE trial data for AXS-12 in narcolepsy with cataplexy at SLEEP 2026
- Presented post-hoc composite endpoint analysis of solriamfetol Phase 3 trials in narcolepsy and OSA
- Presented subgroup analysis from CRESCENDO survey on residual cataplexy symptom burden
- No new approvals, regulatory submissions, or financial guidance were announced
- Conference runs June 14-17, 2026 in Baltimore
Financial Impact
No financial figures disclosed; routine scientific conference presentations with no immediate revenue or cost impact
Risk Factors
- AXS-12 and solriamfetol pipeline progress remains subject to clinical and regulatory risks
- No new efficacy or safety signals that change the probability of approval
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3311661 |
Track record
26 reports on AXSM
6 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +14.74% at T+60 after the Apr 30, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 2, 202614d ago 8-K Bullish 6/10 No price data
- Nov 2, 202614d ago Press Release Bullish 6/10 Entry $136.01 to $133.96 Now $137.01 +0.74% ▼ −1.51% −1.59% vs SPY
- Oct 20, 202627d ago Institutional Cluster Bearish 4/10 Entry $156.31 to $142.20 Now $137.01 +12.35% ▲ +9.03% +8.58% vs SPY
- Aug 11, 202613w ago Institutional Cluster Mixed 5/10 Entry $214.66 to $218.20 Now $137.01 −36.17% ▲ +1.65% +2.09% vs SPY
- Aug 10, 202614w ago 8-K Neutral 6/10 No price data
- Aug 10, 202614w ago Press Release Mixed 6/10 Entry $220.89 to $216.27 Now $137.01 −37.97% ▼ −2.09% −2.04% vs SPY
- Jul 15, 202617w ago Press Release Bullish 6/10 Entry $237.53 to $239.62 Now $137.01 −42.32% ▲ +0.88% +1.86% vs SPY
- Jul 9, 202618w ago Court Ruling Bullish 5/10 Entry $248.95 to $237.04 Now $137.01 −44.96% ▼ −4.78% −4.65% vs SPY
- Jul 7, 202618w ago Press Release Neutral 4/10 Entry $249.76 to $235.26 Now $137.01 −45.14% ▼ −5.81% −6.36% vs SPY
- Jul 1, 202619w ago 144 Neutral 4/10 Entry $244.31 to $248.95 Now $137.01 −43.92% ▲ +1.90% +0.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers